

Xolair (omalizumab) Non-Oncology Treatment Order Set

1. Patient Name:		
2. DOB:	Height (inches):	Weight (lbs):
3. Diagnosis:		
[] J45.51 Severe persistent asthma with (acute) exacerbat	ion [] J45.41 Moderate pers	istent asthma with (acute) exacerbation
[] J45.50 Severe persistent asthma, uncomplicated	[] J45.40 Moderate pers	istent asthma, uncomplicated
[] J45.52 severe persistent asthma with status asthmaticu	s [] J45.42 Moderate pers	istent asthma with status asthmaticus
[] Other ICD-10 Code: Diagnosis	s description:	
HOACNY will obtain authorization for drug administration prior to this medication not being in alignment with the insurance pla administer the medication.		
4. Pre-medications:		
[] Acetaminophen:		
[] 1000mg PO [] 500mg PO		
[] Diphenhydramine:		
[] 25mg PO [] 50mg PO [] 25	img IV [] 50mg IV	
[] Hydrocortisone: 100mg IVP		
[] Other Pre-medication:		
 [] No Pre-medications indicated 		
-	/biosimilar	
5. Drug Order: Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 375mg/dose [] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
[] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie 6. Infusion Lab Requirements: [] CBC with differential annually	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Da administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & comper the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the complications associated with drug administration as well as drug specifie 6. Infusion Lab Requirements:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Da administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & coper the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie 6. Infusion Lab Requirements: [] CBC with differential annually [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Do Next Do administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & of per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie 6. Infusion Lab Requirements: [] CBC with differential annually [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN The prescribing physician is responsible for ordering, obtaining, reviewing	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Do Next Do administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & of per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie 6. Infusion Lab Requirements: [] CBC with differential annually [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN The prescribing physician is responsible for ordering, obtaining, reviewing	5mg/dose [] 300mg/dose img/dose [] 150mg/dose img/dose [] 150mg/dose mg/dose [] 150mg/dose img/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies. 6. Infusion Lab Requirements: [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIT The prescribing physician is responsible for ordering, obtaining, reviewing 7. Baseline Lab/Testing completed: [] Serum IgE level, date: [] CE	5mg/dose [] 300mg/dose img/dose [] 150mg/dose img/dose [] 150mg/dose mg/dose [] 150mg/dose img/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies. 6. Infusion Lab Requirements: [] CBC with differential annually [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIT The prescribing physician is responsible for ordering, obtaining, reviewing 7. Baseline Lab/Testing completed: [] Serum IgE level, date: [] CE	5mg/dose [] 300mg/dose img/dose [] 150mg/dose img/dose [] Next Do administration, post-infusion observents events condition or delayed adverse events events e prescribing physician is responsible is responsible is monitoring parameters before produce monitoring parameters before produce INISTRATION. g all laboratory results & providing co 3C, date: [] Oth	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received HOA of CNY is responsible to provide nursing care, safe drug handling & comported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies. Any changes in the complications associated with drug administration as well as drug specifies. 6. Infusion Lab Requirements: [] CBC with differential annually [] Other: [] No labs monitoring HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADM. The prescribing physician is responsible for ordering, obtaining, reviewing 7. Baseline Lab/Testing completed: [] Serum IgE level, date: [] CE 8. Patient Assistance & REMS Program Enrollment	5mg/dose [] 300mg/dose img/dose [] 150mg/dose img/dose [] Next Do administration, post-infusion observ condition or delayed adverse events prescribing physician is responsible ic monitoring parameters before pro INISTRATION. g all laboratory results & providing c 3C, date: [] Oth program.	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy [] Continuing therapy: Last Dose Received	5mg/dose [] 300mg/dose img/dose [] 150mg/dose img/dose [] Next Do administration, post-infusion observ condition or delayed adverse events prescribing physician is responsible is responsible ic monitoring parameters before produce [] Oth INISTRATION. [] Oth 3C, date: [] Oth program. ams.	[] 225mg/dose [] 300mg/dose